EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. & Encourages Inves...
October 05 2016 - 7:10PM
Business Wire
Khang & Khang LLP (the “Firm”) announces a class action
lawsuit has been filed against Seres Therapeutics (“Seres” or the
“Company”) (Nasdaq: MCRB). Investors who purchased or otherwise
acquired shares between June 25, 2015 and July 29, 2016 inclusive
(the “Class Period”), are encouraged to contact the Firm prior to
the November 28, 2016 lead plaintiff motion deadline.
If you purchased shares of Seres during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von
Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
The complaint alleges that during the Class Period, Seres made
materially false and misleading statements and/or failed to
disclose material facts about its lead drug product candidate
SER-109, praising its potential and efficacy. On July 29, 2016, the
Company announced that the Phase 2 clinical trial of SER-109 did
not meet its primary endpoint. When this information was released
to the public, shares of Seres dropped in value, which caused
investors harm.
If you wish to learn more about this lawsuit, or if
you have questions regarding this notice or your rights, please
contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or via e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161005006525/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024